Related references
Note: Only part of the references are listed.Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons
Antoine Hollebecque et al.
EUROPEAN JOURNAL OF CANCER (2015)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Yasushi Totoki et al.
NATURE GENETICS (2014)
Exploration of liver cancer genomes
Tatsuhiro Shibata et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Mammalian target of rapamycin inhibition in hepatocellular carcinoma
Rene E. Ashworth et al.
WORLD JOURNAL OF HEPATOLOGY (2014)
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
Richard S. Finn et al.
JOURNAL OF HEPATOLOGY (2013)
Phase 1/2 Study of Everolimus in Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
CANCER (2011)
Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Anne-Christine Piguet et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
Hung Huynh et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma
Zheng Wang et al.
CLINICAL CANCER RESEARCH (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
Haesun Choi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma
JL Steel et al.
ANNALS OF ONCOLOGY (2006)
Patients' estimation of overall treatment burden: Why not ask the obvious?
J Bernhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Sample size tables for exact single-stage phase II designs
RP A'Hern
STATISTICS IN MEDICINE (2001)
Share Paper
